Abstract:Metal-based complexes have occupied a pioneering niche in the treatment of many chronic diseases, including various types of cancers. Despite the phenomenal success of cisplatin for the treatment of many solid malignancies, a limited number of metallo-drugs are in clinical use against cancer chemotherapy till date. While many other prominent platinum and non‑platinum- based metallo-drugs (e.g. NAMI-A, KP1019, carboplatin, oxaliplatin, titanocene dichloride, casiopeinas® etc) have entered clinical trials, many have failed at later stages of R&D due to deleterious toxic effects, intrinsic resistance and poor pharmacokinetic response and low therapeutic efficacy. Nonetheless, research in the area of medicinal inorganic chemistry has been increasing exponentially over the years, employing novel target based drug design strategies aimed at improving pharmacological outcomes and at the same time mitigating the side-effects of these drug entities. Over the last few decades, natural products became one of the key structural motifs in the anticancer drug development. Many eminent researchers in the area of medicinal chemistry are devoted to develop new 3d-transition metal-based anticancer drugs/repurpose the existing bioactive compounds derived from myriad pharmacophores such as coumarins, flavonoids, chromones, alkaloids etc. Metal complexes of natural alkaloids and their analogs such as luotonin A, jatrorrhizine, berberine, oxoaporphine, 8-oxychinoline etc. have gained prominence in the anticancer drug development process as the naturally occurring alkaloids can be anti-proliferative, induce apoptosis and exhibit inhibition of angiogenesis with better healing effect. While some of them are inhibitors of ERK signal-regulated kinases, others show activity based on cyclooxygenases-2 (COX-2) and telomerase inhibition. However, the targets of these alkaloid complexes are still unclear, though it is well-established that they demonstrate anticancer potency by interfering with multiple pathways of tumorigenesis and tumor progression both in vitro and in vivo. Over the last decade, many significant advances have been made towards the development of natural alkaloid-based metallo-drug therapeutics for intervention in cancer chemotherapy that have been summarized below and reviewed in this article.

Metal Anticancer Complexes – Activity, Mechanism of Action, Future Perspectives

Anticancer Metallocenes and Metal Complexes of Transition Elements from Groups 4 to 7

Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides-Current Developments in Structure-Activity Relationship

Metallic Nanoclusters for Cancer Imaging and Therapy.

Metal Complexes in Medicine: Design and Mechanism of Action

Metal Complexes of Natural Product Like-compounds with Antitumor Activity.

Research Progress of Metal Anticancer Drugs

Metal-mediated Immune Regulations and Interventions: Prospects of the Emerging Field of Metalloimmunology

A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies

Multi-Target Metal-Based Anticancer Agents

A promising future of metal‐N‐heterocyclic carbene complexes in medicinal chemistry: The emerging bioorganometallic antitumor agents

A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs

Metal-N-heterocyclic carbene complexes as anti-tumor agents

Towards the Rational Design of Platinum(ii) and Gold(iii) Complexes As Antitumour Agents

Metal Complexes Induced Ferroptosis for Anticancer Therapy

Metal-based Anticancer Chemotherapeutic Agents.

Anticancer and Antibiotic Rhenium Tri- and Dicarbonyl Complexes: Current Research and Future Perspectives

Anticancer Mechanism of Novel Metal Drugs with Different Metal Centers

New Strategies and Trends for the Design of Metal-Based Anticancer Drugs

Metallo-Drugs in Cancer Therapy: Past, Present and Future

Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects